Vor Biopharma (VOR) Earnings Analysis

Vor Biopharma (VOR) has no confirmed upcoming earnings date. Last quarter (2026-03-30) it beat with EPS 44.5 USD vs -1.14 USD est (+4003.5%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -0.03.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does VOR next report earnings?

No confirmed upcoming earnings date is currently scheduled for VOR. This page updates as the calendar is published.

VOR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-3044.5 USD-1.14 USD+4003.5%Beat
2025-11-13-3.33 USD-3.06 USD-8.8%Miss
2025-05-14-0.26 USD-0.25 USD-4%Miss
2025-03-20-0.44 USD-0.34 USD-29.4%Miss

Beat rate: 1/4 (25%) over reported quarters with consensus data.

VOR valuation and analyst view

Trailing P/E-0.03
Trailing EPS-2,053.12533 USD
Price / book-0.06
Dividend yield0.00%
Market cap0.13B
Analyst consensusBuy (10 buy / 3 hold / 0 sell)
Avg price target18 USD

Related research pages

Frequently asked questions

When is Vor Biopharma (VOR)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for VOR. This page updates as the calendar is published.

Did VOR beat earnings last quarter?

In its 2026-03-30 report, VOR posted EPS of 44.5 USD versus a -1.14 USD estimate — a beat of 4003.5%.

What is VOR's earnings track record?

Over the last 4 reported quarters with consensus data, VOR beat estimates 1 times (25%).

What is VOR's current P/E ratio and EPS?

VOR trades at a trailing P/E of -0.03 on trailing EPS of -2053.125326947444 USD.

What do analysts rate VOR?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 18 USD.